T1	Participants 90 114	chronic myeloid leukemia
T2	Participants 283 313	chronic myeloid leukemia (CML)
T3	Participants 556 610	376 patients with newly diagnosed CML in chronic phase
T4	Participants 636 687	340 patients were Ph/BCR-ABL positive and evaluable
T5	Participants 949 1028	534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU)
T7	Participants 1639 1651	534 patients
